Breast implant-associated anaplastic large cell lymphoma in the post-mastectomy setting: Clinical and therapeutic implications

We report a case of breast implant-associated anaplastic large cell lymphoma in a 70-year old woman, who 21 years previously had undergone bilateral breast augmentation with textured silicone implants. Eleven years later, she had bilateral implant removal with possible implant leak and presence of ‘atypical cells’ in the seroma. She then opted for prophylactic bilateral mastectomy in view of her strong family history of breast cancer and underwent reconstruction with subcutaneous gel implants. Eight months later, the patient noted right breast swelling and peri-implant effusion. The cytology was suspicious for lymphoma. Bilateral implant removal and capsulectomy was performed and a breast implant-associated anaplastic large cell lymphoma was diagnosed. Due to the lack of surrounding breast tissue after mastectomy, it was not possible to thoroughly sample or evaluate breast parenchymal involvement by the lymphoma, an important consideration in determining aggressivity. The decision was made to initiate Brentuximab vedotin therapy.
Source: Human Pathology: Case Reports - Category: Pathology Source Type: research

Related Links:

The tumor suppressor protein phosphatase 2A (PP2A) is a serine/threonine phosphatase whose activity is inhibited in most human cancers. One of the best-characterized PP2A substrates is MYC proto-oncogene basic helix–loop–helix transcription factor (MYC), whose overexpression is commonly associated with aggressive forms of this disease. PP2A directly dephosphorylates MYC, resulting in its degradation. To explore the therapeutic potential of direct PP2A activation in a diverse set of MYC-driven cancers, here we used biochemical assays, recombinant cell lines, gene expression analyses, and immunohistochemistry to ...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Cell Biology Source Type: research
Authors: Zappulo E, Scotto R, Buonomo AR, Maraolo AE, Pinchera B, Gentile I Abstract Introduction: Hepatitis C virus (HCV) is estimated to infect approximately 70 million people worldwide. If left untreated, chronic infection can progress to cirrhosis, liver failure or hepatocellular carcinoma. The advent of new direct-acting antivirals (DAA) has revolutionized patients' chances of treatment and viral elimination. Currently, several DAA options are available on the market.Areas covered: This review focuses on the pharmacokinetics, efficacy, tolerability and safety profile of DCV-TRIO, a twice-daily fixed-dose combi...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
ConclusionsThere is under- and mistimed use of PP-G-CSF among patients at HR for FN. Novel pegfilgrastim delivery devices could help breast cancer patients at HR for FN complete all their cycles with timely prophylaxis.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Exclusive: solicitors call for UK ban of textured variety associated with lymphomaAt least 61 women in the UK have been diagnosed with a potentially fatal cancer linked to breast implants, but the type they received continues to be used, with no plans by the regulator to follow France and Australia in banning them.Lawyers for more than 40 of the women, who are bringing legal action against the manufacturers as well as the clinics and doctors who carried out the surgery, say thetextured implants linked toanaplastic large cell lymphoma (ALCL) should be withdrawn from the market. Smooth implants are available instead, which h...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Breast cancer Health Society Cancer research Medical research Science Pharmaceuticals industry Business UK news Source Type: news
Publication date: Available online 3 January 2020Source: Seminars in Cancer BiologyAuthor(s): Kelly Olino, Tristen Park, Ntia AhujaAbstractAdvances in immunotherapy, most notably antibodies targeting the inhibitory immune receptors cytotoxic T-lymphocyte associated protein 4 (CTLA-4/CD152), programmed death protein 1 (PD-1/CD279) and programmed death-ligand 1 (PD-L1/B7H1/CD274) have become effective standard therapies in advanced malignancies including melanoma,1–4 merkel cell carcinoma5, urological cancers6–8, non-small cell lung cancer9–11, mis-match repair (MMR) deficient tumors12, and Hodgkin lymphoma...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
We report about a 67 years old man with cerebellar symptoms and a weight loss of 10 kg who was treated in our clinic. After our diagnostic work up we found a non small cell cancer and diagnosed a subacute degeneration of the cerebellum as a paraneoplastic disorder. We found a high positive titer for Anti-Tr3 antibodies while the rest of the paraneoplastic antibodies described as typically associated with the subacute degeneration of the cerebellum were negative. The Anti-Tr3 antibodies are usually found in patients with Hodgkin and less often Non-Hodgkin disease. After initiation of a tumor specific therapy and intraveno...
Source: Der Nervenarzt - Category: Neurology Authors: Tags: Nervenarzt Source Type: research
Publication date: Available online 30 December 2019Source: Seminars in Cancer BiologyAuthor(s): Biagio Ricciuti, Giuseppe Lamberti, Elisa Andrini, Carlo Genova, Andrea De Giglio, Vanessa Bianconi, Amirhossein Sahebkar, Rita Chiari, Matteo PirroAbstractWith 9.6 million deaths in 2018, cancer represents one of the most common causes of death, both in men and women. Despite recent advances in the understanding of molecular mechanisms involved in cancer development and progression, treatment options are still limited. Limitations of traditional chemotherapy include the lack of selectivity and the unfavorable safety profile. Th...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
ConclusionConsidering the high costs for developing a new anticancer agent, we used the FDA-approved drugs gemcitabine, romidepsin (is approved for T-cell lymphoma and is under clinical trial for TNBC), and cisplatin to economically formulate an efficacious and safe combination regimen. The highly efficacious gemcitabine plus romidepsin  + cisplatin regimen should be poised for efficient translation into clinical trials, ultimately contributing to reduced mortality and improved quality of life for TNBC patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Diffuse large B-cell lymphomas (DLBCLs) are uncommon in the mouth; however, they are the commonest type of non-Hodgkin lymphomas at this site. Preferentially, they affect tonsils and their occurrence in the upper lip is rare. This work reports a case of DLBCL arising in the left upper lip of a 73-year-old white woman that was recently diagnosed as having advanced breast cancer besides being a carrier of Parkinson and Alzheimer diseases. The mucosal surface of the upper lip displayed a solitary, fast-growing, painful, ulcerated, reddish, and sessile 4-cm-sized swelling without cervical lymph node involvement at presentation.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research
by Simon Mathis K ønig, Vendela Rissler, Thilde Terkelsen, Matteo Lambrughi, Elena Papaleo Apoptosis is an essential defensive mechanism against tumorigenesis. Proteins of the B-cell lymphoma-2 (Bcl-2) family regulate programmed cell death by the mitochondrial apoptosis pathway. In response to intracellular stress, the apoptotic balance is governed by interactions of three distinct subg roups of proteins; the activator/sensitizer BH3 (Bcl-2 homology 3)-only proteins, the pro-survival, and the pro-apoptotic executioner proteins. Changes in expression levels, stability, and functional impairment of pro-survival prote...
Source: PLoS Computational Biology - Category: Biology Authors: Source Type: research
More News: Breast Augmentation | Breast Cancer | Cancer | Cancer & Oncology | Cytology | Lymphoma | Mastectomy | Pathology | Plastic Surgery